GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
First Claim
Patent Images
1. A method of detecting impaired glucose tolerance of individuals by evaluation of β
- -cells secretory capacity, comprising;
infusing the individual with glucose and a glucagon-like peptide-1 or its biologically active analogue, wherein said analogue binds to the glucagon-like peptide-1 amide receptor protein and has a corresponding biological effect on insulin secretion as GLP-1 (7-36) amide; and
thereafter measuring the insulin and C-peptide responses against standard responses of healthy subjects to determine if the individual has impaired β
-cell function.
3 Assignments
0 Petitions
Accused Products
Abstract
Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in β-cell stimulatory tests in order to test β-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.
-
Citations
13 Claims
-
1. A method of detecting impaired glucose tolerance of individuals by evaluation of β
- -cells secretory capacity, comprising;
infusing the individual with glucose and a glucagon-like peptide-1 or its biologically active analogue, wherein said analogue binds to the glucagon-like peptide-1 amide receptor protein and has a corresponding biological effect on insulin secretion as GLP-1 (7-36) amide; and
thereaftermeasuring the insulin and C-peptide responses against standard responses of healthy subjects to determine if the individual has impaired β
-cell function.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- -cells secretory capacity, comprising;
Specification